Clincosm LogoSign in Get a demo

toripalimab

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)

Recruiting
  • Toripalimab
  • First-line Treatment
  • Guangzhou, Guangdong, China
    Sun Yat-sen University cancer center
Mar 7, 2023

Toripalimab, Radiation Trial in Hangzhou (Toripalimab, CRT, SCRT)

Recruiting
  • Toripalimab
  • Radiation
  • Hangzhou, Zhejiang, China
    Zhengjiang Cancer Hospital
Dec 29, 2022

Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma Trial in Nanning (Toripalimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • +2 more
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Aug 16, 2021

Radiotherapy, Toripalimab, Sorafenib Trial in Beijing (Radiotherapy plus Toripalimab, Sorafenib)

Recruiting
  • Radiotherapy
  • +3 more
  • Beijing, Beijing, China
    Bo Chen
Mar 6, 2021

Gastric Cancer, Gastro-oesophageal Junction Cancer, Immunotherapy Trial in Shanghai (Anlotinib Plus Toripalimab)

Recruiting
  • Gastric Cancer
  • +4 more
  • Anlotinib Plus Toripalimab
  • Shanghai, China
    Department of Medical Oncology, Shanghai Changzheng Hospital
Dec 28, 2020

Hepatocellular Carcinoma, Bevacizumab, Liver Tumors Trial (Hepatic arterial infusion chemo, Bevacizumab, Toripalimab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • (no location specified)
Nov 12, 2020

Diffuse Large B-cell Lymphoma, Rituximab, Toripalimab Trial in Beijing (Toripalimab combine with Rituximab)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • +2 more
  • Toripalimab combine with Rituximab
  • Beijing, China
    Cancer Institute/Hospital, Chinese Academy of Medical Sciences &
Jun 12, 2020